No price history available.
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 514 | 455 | 534 | 493 | 488 | 501 | N/A | N/A |
| Operating profit | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | €m | 26 | 29 | 45 | 36 | 11 | 33 | N/A | N/A |
| EPS reported | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Boiron S.A. is a global pharmaceutical company specializing in the production and distribution of homeopathic remedies across France, Europe, North America, and other international markets. Its extensive product portfolio encompasses a range of non-prescription, proprietary, and well-known branded homeopathic treatments. Noteworthy branded offerings include Oscillococcinum, designed to alleviate flu-like symptoms such as fever, chills, headaches, and body aches; Stodal and Stodaline, formulated for cough relief; Arnigel, providing topical support for minor, closed-wound traumas; Camilia, a solution for infant teething discomfort; and Sédatif PC, aimed at managing anxiety, emotional distress, and mild sleep disturbances. Furthermore, its homeopathic range features Coryzalia for addressing cold symptoms and rhinitis; Homéoptic, which targets eye discomfort and irritation in both adults and children; and Homéovox, developed for vocal issues. Beyond its core homeopathic line, Boiron also supplies dietary supplements; Dermoplasmine products (stick, balm, and mousse) for dry skin and lips; Mag' Nuit, an aid for promoting sleep; Arnitrosium for joint pain management; Castor Equi Boiron ointment for cracked skin; and Storinyl syrup for cold symptoms. The company's diverse inventory extends to herbal remedies, exemplified by Canephron, which supports increased urine production and improved urinary tract function; moisturizing lotions for babies; and medical devices, such as COVID-19 self-testing kits and rapid antigen tests. Boiron distributes its extensive product catalog through a comprehensive network encompassing distribution centers, independent pharmacies, pharmacy chains, wholesale partners, grocery and drugstores, specialized health food outlets, and various online retail platforms. Established in 1932, Boiron S.A. maintains its corporate headquarters in Messimy, France.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Boiron S.A. is a global pharmaceutical company specializing in the production and distribution of homeopathic remedies across France, Europe, North America, and other international markets. Its extensive product portfolio encompasses a range of non-prescription, proprietary, and well-known branded homeopathic treatments. Noteworthy branded offerings include Oscillococcinum, designed to alleviate flu-like symptoms such as fever, chills, headaches, and body aches; Stodal and Stodaline, formulated for cough relief; Arnigel, providing topical support for minor, closed-wound traumas; Camilia, a solution for infant teething discomfort; and Sédatif PC, aimed at managing anxiety, emotional distress, and mild sleep disturbances. Furthermore, its homeopathic range features Coryzalia for addressing cold symptoms and rhinitis; Homéoptic, which targets eye discomfort and irritation in both adults and children; and Homéovox, developed for vocal issues. Beyond its core homeopathic line, Boiron also supplies dietary supplements; Dermoplasmine products (stick, balm, and mousse) for dry skin and lips; Mag' Nuit, an aid for promoting sleep; Arnitrosium for joint pain management; Castor Equi Boiron ointment for cracked skin; and Storinyl syrup for cold symptoms. The company's diverse inventory extends to herbal remedies, exemplified by Canephron, which supports increased urine production and improved urinary tract function; moisturizing lotions for babies; and medical devices, such as COVID-19 self-testing kits and rapid antigen tests. Boiron distributes its extensive product catalog through a comprehensive network encompassing distribution centers, independent pharmacies, pharmacy chains, wholesale partners, grocery and drugstores, specialized health food outlets, and various online retail platforms. Established in 1932, Boiron S.A. maintains its corporate headquarters in Messimy, France.